1
|
Salhi S, Doreille A, Dancer MS, Boueilh A, Filipozzi P, El Karoui K, Ponce F, Lebre AS, Raymond L, Mesnard L. Monoallelic Loss-of-Function IFT140 Pathogenic Variants Cause Autosomal Dominant Polycystic Kidney Disease: A Confirmatory Study With Suspicion of an Additional Cardiac Phenotype. Am J Kidney Dis 2024; 83:688-691. [PMID: 37844724 DOI: 10.1053/j.ajkd.2023.08.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 07/28/2023] [Accepted: 08/27/2023] [Indexed: 10/18/2023]
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease. While biallelic variants affecting IFT140 are responsible for Mainzer-Saldino syndrome (characterized by severe ciliopathy causing skeletal abnormalities, kidney disease, and cysts), monoallelic loss-of-function (LoF) variants have been recently reported as an important cause of ADPKD beyond PKD1/2 genes. Herein, we report 6 non-family-related cases of monoallelic IFT140 LoF variants, identified from 1,340 exomes sequenced for nephrological indications in our local database. Every patient presented with polycystic kidney disease. Furthermore, the mother of a boy diagnosed with Mainzer-Saldino syndrome with a biallelic variant affecting IFT140 presented with several bilateral cysts, revealed after kidney imaging, and was found to carry a pathologic frameshift IFT140 variation. As well as this particular Mainzer-Saldino case, our 6 additional patients confirm that heterozygous IFT140 frameshift variants are responsible for the cystic phenotype and kidney failure. Interestingly, of the 6 patients, 2 also exhibited dilated cardiomyopathy, which was of unknown origin, as no genetic cause was found after exome sequencing analysis, suggesting a potential connection between IFT140 and heart disease.
Collapse
Affiliation(s)
- Sofiane Salhi
- Service des Soins intensifs Néphrologiques et Rein Aigu, Hôpital Tenon, Assistance Publique- Hôpitaux de Paris, Paris, France; Université Paul Sabatier - Toulouse 3, Toulouse, France; Toulouse, France Department of Nephrology and Organ Transplantation, Centre for Rare Kidney Diseases, University Hospital of Toulouse, Toulouse, France
| | - Alice Doreille
- Service des Soins intensifs Néphrologiques et Rein Aigu, Hôpital Tenon, Assistance Publique- Hôpitaux de Paris, Paris, France; Faculté de médecine, Sorbonne Université, Paris, France
| | | | - Anna Boueilh
- Service de Néphrologie, Hôpital Henri Mondor, Université Paris Est Créteil, Assistance Publique- Hôpitaux de Paris, Paris, France
| | - Pierre Filipozzi
- Service de Néphrologie, Hôpital Robert Schuman, Association Saint-André, Metz, France
| | - Khalil El Karoui
- Service de Néphrologie et Dialyses, Hôpital Tenon, Assistance Publique- Hôpitaux de Paris, Paris, France
| | - Fanny Ponce
- Centre Hospitalier Universitaire de Reims, Pôle de biologie médicale et pathologie, Service de génétique, Reims, France et Université Reims Champagne Ardenne (URCA), Reims, France
| | - Anne-Sophie Lebre
- Centre Hospitalier Universitaire de Reims, Pôle de biologie médicale et pathologie, Service de génétique, Reims, France et Université Reims Champagne Ardenne (URCA), Reims, France; Department of Medical Genetics, AP-HP Sorbonne University, Paris, France
| | - Laure Raymond
- Laboratoire de Génétique, Eurofins Biomnis, Lyon, France
| | - Laurent Mesnard
- Service des Soins intensifs Néphrologiques et Rein Aigu, Hôpital Tenon, Assistance Publique- Hôpitaux de Paris, Paris, France; Faculté de médecine, Sorbonne Université, Paris, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche S1155, Paris, France; Institut des Sciences du Calcul et des Données, Sorbonne Université, Paris, France; French National Center for Hereditary Kidney Diseases in Children and Adults (MARHEA).
| |
Collapse
|
2
|
Salhi S, Doreille A, Dancer M, Boueilh A, Filipozzi P, El Karoui K, Ponce F, Raymond L, Lebre A, Mesnard L. Variant monoallélique IFT140 et polykystose rénale. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Frimat L, Gavet L, Filipozzi P, Laurain E, Kessler M, Brunaud L, Ayav C. FP605MINIMAL IMPACT OF CALCIMIMETICS ON THE MANAGEMENT OF HYPERPARATHYROIDISM IN CHRONIC DIALYSIS: 5-YEAR FOLLOW-UP. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fp605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Luc Frimat
- Department of Nephrology, CHRU Nancy, Vandoeuvre les Nancy, France
| | - Lucille Gavet
- Department of Nephrology, CHRU Nancy, Vandoeuvre les Nancy, France
| | - Pierre Filipozzi
- Department of Nephrology, CHRU Nancy, Vandoeuvre les Nancy, France
| | | | - Michèle Kessler
- Department of Nephrology, CHRU Nancy, Vandoeuvre les Nancy, France
| | - Laurent Brunaud
- Department of Surgery, CHRU Nancy, Vandoeuvre les Nancy, France
| | - Carole Ayav
- CIC1433 Clinical Epidemiology, Inserm, CHRU Nancy, Vandoeuvre les Nancy, France
| |
Collapse
|
4
|
Filipozzi P, Ayav C, Ngueyon Sime W, Laurain E, Kessler M, Brunaud L, Frimat L. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study. BMJ Open 2017; 7:e011482. [PMID: 28348181 PMCID: PMC5372074 DOI: 10.1136/bmjopen-2016-011482] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVES To define groups of patients according to the changes of biochemical parameters, that is, serum calcium, phosphate and parathyroid hormone (PTH), over a 2-year follow-up period using group-based multi-trajectory modeling (GBMM) among a cohort of dialysis patients with newly diagnosed secondary hyperparathyroidism (SHPT) (ie, PTH≥500 ng/L for the first time) and to compare their patient characteristics and treatments. DESIGN Pharmacoepidemiological study. SETTING In the 12 dialysis units located in the French region of Lorraine. PARTICIPANTS A total of 269 dialysis patients with newly diagnosed SHPT were prospectively included from December 2009 to May 2012 and followed-up for 2 years. RESULTS We identified four distinct trajectory groups: 'rapid PTH drop' experiencing a rapid and sharp decrease (over weeks) in PTH level associated with decreasing phosphate level within normal range (n=34; 12.7%), 'gradual PTH decrease' experiencing a gradual and continuous decrease (over months) in PTH level and maintaining phosphate at a middle level throughout the study (n=98; 36.4%), 'slow PTH decrease with high phosphate' experiencing a slow decrease in PTH level associated with a relatively high phosphate level (n=105; 39.0%) and 'uncontrolled SHPT' with high levels of PTH and phosphate throughout the study (n=32; 11.9%). Patients in the 'uncontrolled SHPT' group were significantly (p<0.00001) younger than patients in other groups. Kidney Disease Improving Global Outcomes (KDIGO) targets for PTH, phosphate and calcium were reached simultaneously for 14.9% of patients at baseline and 16.7% at the end of the study. Patients were given cinacalcet more frequently at months 3 and 6 in the 'rapid PTH drop' and at month 24 in the 'uncontrolled SHPT' groups. CONCLUSIONS Over 2 years following a new SHPT diagnosis, a younger age and a higher rate of alkaline phosphatase were associated to a continuous uncontrolled SHPT. Patients with the lowest PTH at the end of the follow-up tended to receive more often cinacalcet. TRIAL REGISTRATION NUMBER ClinicalTrials.gov number, NCT02888639, post results.
Collapse
Affiliation(s)
- Pierre Filipozzi
- Department of Nephrology, University Hospital, Vandœuvre-lès-Nancy, France
- Néphrolor Network of Care, Vandœuvre-lès-Nancy, France
| | - Carole Ayav
- Néphrolor Network of Care, Vandœuvre-lès-Nancy, France
- Pôle S2R, Epidemiology and Clinical Evaluation, University Hospital, Vandœuvre-lès-Nancy, France
| | - Willy Ngueyon Sime
- Pôle S2R, Epidemiology and Clinical Evaluation, University Hospital, Vandœuvre-lès-Nancy, France
| | - Emmanuelle Laurain
- Department of Nephrology, University Hospital, Vandœuvre-lès-Nancy, France
- Néphrolor Network of Care, Vandœuvre-lès-Nancy, France
| | - Michèle Kessler
- Department of Nephrology, University Hospital, Vandœuvre-lès-Nancy, France
- Néphrolor Network of Care, Vandœuvre-lès-Nancy, France
| | - Laurent Brunaud
- Department of Hepatobiliary, Digestive and Endocrine Surgery, University Hospital, Vandœuvre-lès-Nancy, France
| | - Luc Frimat
- Department of Nephrology, University Hospital, Vandœuvre-lès-Nancy, France
- Néphrolor Network of Care, Vandœuvre-lès-Nancy, France
- Lorraine University, Paris Descartes University, Nancy, France
| |
Collapse
|
5
|
Le-Berre N, Filipozzi P, Martin L, Frimat L, Girerd S. Glomérulonéphrite aiguë post-infectieuse à Streptococcus equi subsp. zooepidemicus : premier cas décrit en France. Nephrol Ther 2017; 13:37-41. [DOI: 10.1016/j.nephro.2016.07.448] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 07/09/2016] [Accepted: 07/25/2016] [Indexed: 11/30/2022]
|
6
|
Brunaud L, Ngueyon Sime W, Filipozzi P, Nomine-Criqui C, Aronova A, Zarnegar R, Kessler M, Frimat L, Ayav C. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis. Surgery 2015; 159:183-91. [PMID: 26476826 DOI: 10.1016/j.surg.2015.06.058] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Revised: 04/30/2015] [Accepted: 06/03/2015] [Indexed: 10/22/2022]
Abstract
BACKGROUND The calcimimetic drug cinacalcet has changed the prescription patterns in patients with secondary hyperparathyroidism, despite the lack of randomized studies that compare cinacalcet with conventional treatment, including parathyroidectomy. The aim of this study was to evaluate current management of patients on chronic dialysis with incidental and parathyroid hormone (PTH) levels ≥ 500 ng/L. METHODS Prospective pharmacoepidemiologic study of chronic dialysis patients with PTH level ≥ 500 ng/L. RESULTS We studied 269 patients. Among the 186 patients who had 2-year follow-up, 125 (67%) were managed using cinacalcet. At 2 years, when comparing the cinacalet with the noncinacalet groups, we found that mean PTH values were 400 ± 318 versus 388 ± 251 ng/L (P = ns) and the percentage of patients following 2009 PTH Kidney Disease Improving Global Outcomes (KDIGO) guidelines were 79 versus 85% (P = ns). Eight patients (4%) underwent parathyroidectomy. On multivariate analysis, the use of cinacalcet was not a predictor for PTH within KDIGO guidelines at 2-year follow-up. CONCLUSION Cinacalcet was used in the majority (67%) of patients on chronic dialysis with secondary hyperparathyroidism, but the use of cinacalcet did not affect mean PTH values nor the proportion of patients following KDIGO guidelines compared with patients not using calcimimetics.
Collapse
Affiliation(s)
- Laurent Brunaud
- University de Lorraine, CHU Nancy - Hospital Brabois Adultes, Department of Digestive, Hepato-Biliary and Endocrine Surgery, Nancy, France; INSERM U954, University de Lorraine, Faculty de medicine, Nancy, France.
| | - Willy Ngueyon Sime
- University de Lorraine, CHU Nancy, Pôle S2R, Epidémiologie et Evaluation Cliniques, INSERM, CIC-EC1433, Nancy, France
| | - Pierre Filipozzi
- University de Lorraine, CHU Nancy, Pôle S2R, Epidémiologie et Evaluation Cliniques, INSERM, CIC-EC1433, Nancy, France; University de Lorraine, CHU Nancy, Department of Nephrology, Nancy, France
| | - Claire Nomine-Criqui
- University de Lorraine, CHU Nancy - Hospital Brabois Adultes, Department of Digestive, Hepato-Biliary and Endocrine Surgery, Nancy, France
| | - Anna Aronova
- Division of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York, NY
| | - Rasa Zarnegar
- Division of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York, NY
| | - Michelle Kessler
- University de Lorraine, CHU Nancy, Department of Nephrology, Nancy, France
| | - Luc Frimat
- University de Lorraine, CHU Nancy, Department of Nephrology, Nancy, France
| | - Carole Ayav
- University de Lorraine, CHU Nancy, Pôle S2R, Epidémiologie et Evaluation Cliniques, INSERM, CIC-EC1433, Nancy, France; University de Lorraine, CHU Nancy, Department of Nephrology, Nancy, France
| |
Collapse
|
7
|
Peters N, Laurain E, Frimat L, Filipozzi P, Chapelet A, Martin A, Dekeyser M, Cridlig J. Quelles cibles pour adapter la posologie de fer en hémodialyse. Étude pharmaco-épidémiologique. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Peters NO, Jay N, Cridlig J, Chapelet A, Martin A, Dekeyser M, Filipozzi P, Frimat L. FP674TARGETS FOR ADAPTING INTRAVENOUS IRON DOSE IN HEMODIALYSIS: A PHARMACOEPIDEMIOLOGICAL STUDY. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv182.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Filipozzi P, Ayav C, Ngueyon Sime W, Laurain E, Kessler M, Brunaud L, Frimat L. SP651TRAJECTORIES OF CKD-MBD BIOCHEMICAL PARAMETERS IN THE 2 YEARS FOLLOWING DIAGNOSIS OF SEVERE SECONDARY HYPERPARATHYROIDISM. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv199.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Filipozzi P, Ayav C, Erpelding ML, Kessler M, Brunaud L, Frimat L. Influence on quality of life from an early cinacalcet prescription for secondary hyperparathyroidism in dialysis. Pharmacoepidemiol Drug Saf 2014; 24:187-96. [DOI: 10.1002/pds.3683] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 06/18/2014] [Accepted: 07/07/2014] [Indexed: 11/11/2022]
Affiliation(s)
- Pierre Filipozzi
- Department of Nephrology, Dialysis, and Transplantation; CHU Nancy; F-54 511 Vandoeuvre-les-Nancy France
- CHU Nancy, Pôle S2R; Epidémiologie et Evaluation Cliniques; Nancy F-54 000 France
- INSERM; CIC-EC, CIC 1433; Nancy F-54 000 France
| | - Carole Ayav
- CHU Nancy, Pôle S2R; Epidémiologie et Evaluation Cliniques; Nancy F-54 000 France
- INSERM; CIC-EC, CIC 1433; Nancy F-54 000 France
- Université de Lorraine; CIC-EC, CIC 1433; Nancy F-54 000 France
| | - Marie-Line Erpelding
- CHU Nancy, Pôle S2R; Epidémiologie et Evaluation Cliniques; Nancy F-54 000 France
- INSERM; CIC-EC, CIC 1433; Nancy F-54 000 France
- Université de Lorraine; CIC-EC, CIC 1433; Nancy F-54 000 France
| | - Michèle Kessler
- Department of Nephrology, Dialysis, and Transplantation; CHU Nancy; F-54 511 Vandoeuvre-les-Nancy France
| | - Laurent Brunaud
- Department of Hepatobiliary, Digestive and Endocrine Surgery; CHU Nancy; F-54 511 Vandoeuvre-les-Nancy France
| | - Luc Frimat
- Department of Nephrology, Dialysis, and Transplantation; CHU Nancy; F-54 511 Vandoeuvre-les-Nancy France
- Université de Lorraine, Université Paris Descartes; APEMAC, EA4360; Nancy France
| |
Collapse
|
11
|
Filipozzi P. Influence sur la qualité de vie d’une prescription précoce de cinacalcet pour hyperparathyroïdie secondaire en dialyse. Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2013.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
12
|
Filipozzi P, Ayav C, Erpelding M, Brunaud L, Frimat L. Association entre la prescription de cinacalcet et la qualité de vie de patients dialysés lors du diagnostic d’hyperparathyroïdie secondaire sévère. Nephrol Ther 2013. [DOI: 10.1016/j.nephro.2013.07.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|